Clinical Trials on Clear Cell Papillary Renal Tumor

Total 10854 results

Mayo Clinic

Recruiting

Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Clear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Stage I Renal Cell Cancer | Childhood Renal Cell Carcinoma | Stage II Renal Cell Cancer | Stage I Renal Wilms Tumor and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Celldex Therapeutics

Terminated

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Kidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell Carcinoma

United States
Peloton Therapeutics, Inc.

Active, not recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc) | Papillary Renal Cell Carcinoma (Prcc)

United States
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
Agensys, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Carcinoma, Renal Cell | Renal Cell Carcinoma of Papillary Histology | Renal Cell Carcinoma With Clear Cell Histology | Renal Cell Carcinoma With Non-Clear Cell Histology

United States, Canada
Novartis Pharmaceuticals

Completed

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (MACS0460)

Adenocarcinoma | Carcinoma | Renal Cell | Non Clear Cell Renal Carcinoma | Papillary Cell Renal Carcinoma

France, Italy, Belgium, Germany, Spain, Poland
Jonsson Comprehensive Cancer Center
BeiGene; Driven To Cure

Withdrawn

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell Carcinoma

United States
Australian and New Zealand Urogenital and Prostate...

Recruiting

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell Carcinoma

Australia
National Cancer Institute (NCI)

Completed

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
University College, London

Active, not recruiting

A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer (PEACOCC)

Gynecologic Cancer | Advanced Cancer | Clear Cell Tumor

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland
Telix International Pty Ltd
Grand Pharmaceutical (China) Co., Ltd.

Completed

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma (ZIRDOSE-CP)

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell Carcinoma

China
Guru Sonpavde
Pfizer; Hoosier Cancer Research Network

Withdrawn

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Kidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
University of Washington
Merck Sharp & Dohme LLC; Prometheus Laboratories

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
European Organisation for Research and Treatment...
Pfizer

Completed

CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE)

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditions

France, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Association Pour La Recherche des Thérapeutiques...

Completed

Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus (NEORAD)

Clear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal Carcinoma

France
M.D. Anderson Cancer Center

Active, not recruiting

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
Amgen

Completed

AMG 172 First in Human Study in Patients With Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell Adenocarcinoma

France, United States, Germany
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Kidney Medullary Carcinoma | Advanced Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma

United States
Osel, Inc.
National Cancer Institute (NCI); City of Hope Medical Center; Miyarisan Pharmaceuticals...

Recruiting

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Ependymoma | Anaplastic Ependymoma | Clear Cell Ependymoma | Brain Ependymoma | Cellular Ependymoma | Papillary Ependymoma

United States, Canada, Australia, New Zealand
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell Carcinoma

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Clear Cell Renal Cell Carcinoma

United States
University of Texas Southwestern Medical Center

Terminated

Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

United States
Abramson Cancer Center of the University of Pennsylvania
University of Pittsburgh; Rutgers Cancer Institute of New Jersey

Completed

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

United States
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); Howard Hughes Medical Institute

Recruiting

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Kidney Cancer | Renal Cell Carcinoma | Urothelial Carcinoma | Hereditary Leiomyomatosis and Renal Cell Cancer | Metastatic Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | HLRCC | Clear Cell Carcinoma | Metastatic Kidney Cancer | Fumarate Hydratase Deficiency | Succinate...

United States
Millennium Pharmaceuticals, Inc.

Completed

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Clear-cell Metastatic Renal Cell Carcinoma

Spain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
Rennes University Hospital

Completed

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma (RTKI)

Metastatic Clear Cell Renal Cell Carcinoma

France
Radboud University Medical Center

Completed

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

Netherlands
Australian and New Zealand Urogenital and Prostate...
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)

Renal Cell Carcinoma, Clear Cell | Metastatic Kidney Cancer

Australia
National Cancer Institute (NCI)

Terminated

Vandetanib to Treat Advanced Kidney Cancer

Advanced Clear Cell Renal Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

United States, France, Canada, Spain, Italy, Belgium, Austria, Denmark, Germany, Australia, Israel, Russian Federation, Czechia, Norway, Poland, Romania, Japan, Argentina, Ireland, Greece, United Kingdom, Brazil, Sweden, Finland
University of Texas Southwestern Medical Center
Prometheus Laboratories

Completed

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Kidney Cancer | Hereditary Clear Cell Renal Cell Carcinoma

United States

Clinical Trials on Clear Cell Papillary Renal Tumor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations